{"document_type": "article", "byline": {"person": [{"role": "reported", "firstname": "Gina", "organization": "", "rank": 1, "lastname": "CHON"}], "original": "By GINA CHON"}, "news_desk": "Business", "slideshow_credits": null, "abstract": null, "multimedia": [], "headline": {"kicker": "Breakingviews", "content_kicker": "Breakingviews", "main": "Rising Drug Prices Put Big Pharma\u2019s Lobbying to the Test"}, "print_page": null, "keywords": [{"value": "Drugs (Pharmaceuticals)", "is_major": "N", "rank": "1", "name": "subject"}, {"value": "Prices (Fares, Fees and Rates)", "is_major": "N", "rank": "2", "name": "subject"}, {"value": "Lobbying and Lobbyists", "is_major": "N", "rank": "3", "name": "subject"}, {"value": "Mylan Inc", "is_major": "N", "rank": "4", "name": "organizations"}], "snippet": "Drug makers have spent $2.3 billion lobbying Congress over the last decade, which may explain why lawmakers have done little to curb drug prices....", "source": "The New York Times", "lead_paragraph": "Drug makers have spent $2.3 billion lobbying Congress over the last decade, which may explain why lawmakers have done little to curb drug prices.", "word_count": "368", "pub_date": "2016-09-02T04:00:00+0000", "subsection_name": "DealBook", "blog": [], "type_of_material": "News", "section_name": "Business Day", "web_url": "http://www.nytimes.com/2016/09/02/business/dealbook/rising-drug-prices-put-big-pharmas-lobbying-to-the-test.html", "_id": "57c878a795d0e021d7983e06"}